Asset
APITEGROMAB
SCHOLAR ROCK HOLDING CORPORATION COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07047144 | phase2 | recruiting | 2025-09-15 | 2028-11-01 | Scholar Rock, Inc. | A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy |
| NCT03921528 | phase2 | completed | 2019-04-22 | 2021-01-19 | Scholar Rock, Inc. | An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy |
| NCT06445075 | phase2 | completed | 2024-05-21 | 2025-03-04 | Scholar Rock, Inc. | Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese |
| NCT05156320 | phase3 | completed | 2022-04-14 | 2024-12-18 | Scholar Rock, Inc. | Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam |
| NCT05626855 | phase3 | active_not_recruiting | 2023-04-17 | 2026-11-01 | Scholar Rock, Inc. | Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab |
FDA applications (0)
This company has no applications containing this asset.